The HIV/AIDS pandemic has had a devastating global impact causing more than 30 million HIV-1 infections and over 25 million deaths worldwide. In addition, it is estimated that annually over 450,000 infants are infected through mother-to-child transmission (MTCT). Although antiretroviral therapy (ART) is effective to save lives and reduce MTCT, the coverage of ART in treatment-eligible patients in developing countries is only approximately 67% due to the lack of simple, inexpensive and rapid near-patient treatment monitoring tools. To address the unmet need, we propose to develop an HIV-1 viral load monitoring microfluidic platform technology development of a sensitive photonic crystal sensing technology. This technology detects and quantifies the binding of biotargets (e.g., HIV-1 virus particles) to an optical sensing surface due to the change of bulk index of refraction. The resulted shift in the peak wavelength value correlates with the concentration of biotargets in a biological sample. This technology- driven proposal addresses a significant global clinical need and aims to deliver a portable photonic crystal device that can (i) selectively capture HIV-1 from whole blood, (ii) be sensitive within the clinical cut-off (with 10% error range), inexpensive (<$1), rapid (within 30 minutes), and (iii) handle fingerprick whole blood (up to 100 L) to aid i HIV patient care and treatment in resource-constrained settings. The delivery of this photonic crystal-based HIV-1 viral load monitoring microchips can significantly facilitate the expansion of ART in developing countries, achieving universal access to ART to control the AIDS pandemic.

Public Health Relevance

Despite tremendous efforts made to control the HIV/AIDS pandemic, the lack of simple, inexpensive and rapid HIV-1 viral load monitoring tools significantly prevent universal access to antiretroviral therapy (ART) in developing countries. We aim to develop nanostructured photonic crystal devices to measure HIV-1 viral load from unprocessed whole blood samples to guide ART in resource-limited settings without requiring conventional, central laboratory-based HIV-1 RNA nucleic acid amplification technologies. This sensitive nanotechnology enabled microchip can facilitate the global expansion of ART, especially in developing countries, to save lives and reduce transmission.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI120683-03
Application #
9522801
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Fitzgibbon, Joseph E
Project Start
2016-07-18
Project End
2020-06-30
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
3
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Stanford University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94304
Inan, Hakan; Poyraz, Muhammet; Inci, Fatih et al. (2017) Photonic crystals: emerging biosensors and their promise for point-of-care applications. Chem Soc Rev 46:366-388
El Assal, Rami; Gurkan, Umut A; Chen, Pu et al. (2016) 3-D Microwell Array System for Culturing Virus Infected Tumor Cells. Sci Rep 6:39144